{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-035239","form_type":"8-K","ticker":"CYPH","cik":"0001509745","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2024-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.425774+00:00","generated_at":"2026-06-04T15:04:22.254029+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Leap Therapeutics reports FY2023 net loss $81.4M; cash $70.6M; DKN-01 data positive","bullets":["Net loss $81.4M in FY2023 vs $54.6M in FY2022; R&D expenses $73.2M.","Cash and equivalents $70.6M at Dec 31, 2023; research incentive receivables $0.8M.","DeFianCe Part A (CRC): 30% ORR, 93% DCR; median PFS 6.3 months in 2L MSS CRC.","Completed enrollment (170 pts) in DisTinGuish Part C for gastric/GEJ cancer; data expected mid-2024.","Randomized Part B of DeFianCe (130 pts) enrolling; 80 enrolled as of Mar 15, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-035239","json":"https://secwatch.observer/filing/0001104659-24-035239.json","markdown":"https://secwatch.observer/filing/0001104659-24-035239.md","text":"https://secwatch.observer/filing/0001104659-24-035239.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509745/000110465924035239/0001104659-24-035239-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509745/000110465924035239/tm248524d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T15:04:22.254029+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1a4b48eda9c28f1382d5eaf55c6293f01ad7b186","claim":"CYPHERPUNK TECHNOLOGIES INC. reported the year ended December 31, 2023 results: net income $81.4 million.","evidence_excerpt":"Net Loss was $81.4 million for the year ended December 31, 2023,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465924035239/0001104659-24-035239-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Net income","value":"$81.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}